What this means
Researchers used open data on kidney tissue and drug patterns to rank drugs that might target aging cells. This is a computer study, so it suggests ideas but does not prove any drug works.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- Kidney tissue data from 3 groups of people with diabetic kidney disease, plus 45,956 drug pattern records
- Kind of research
- A study
The science
- Original title
- Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study.
- Authors
- Aygüneş-Jafari D, Düzgün Z
- Journal
- Biomedicines
- Published
- Oct 27, 2026
- Study type
- Study
- PMID
- 42940092 ↗
Abstract
Background/Objectives: Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease, and cellular senescence is a tractable therapeutic target; yet prioritizing credible repurposing candidates is difficult because bulk-tissue senescence signals are weak, single-dataset analyses are unstable, and transcriptome-reversal screens overstate novelty. The objective was to build a senescence-anchored, multi-evidence computational prioritization of repurposing candidates for DKD entirely from open data. Methods: Per-sample senescence activity was quantified by single-sample gene set enrichment across three DKD kidney cohorts, and consensus signatures were reversed against 45,956 LINCS L1000 signatures. Candidates were ranked by reversal strength, mechanism, ChEMBL stage, and ClinicalTrials.gov novelty, then assessed for robustness by senotherapeutic enrichment, an external senolytic benchmark, leave-one-cohort-out analysis, drug-target Mendelian randomization, and single-nucleus profiling. Results: Senescence activity was consistently elevated in DKD across all three cohorts, with moderate-to-large effect sizes (rank-biserial 0.32-0.78). Reversal recovered established senotherapeutic classes and nominated the approved JAK inhibitor fedratinib (within the same class, baricitinib reduced albuminuria in a Phase 2 DKD trial); curated senolytics were modestly separated from negatives (AUROC 0.62, 95% CI 0.52-0.72). Filtering yielded 867 mechanism-annotated compounds robust to cohort removal. Drug-target Mendelian randomization was inconclusive, and single-nucleus profiling highlighted endothelial activation rather than a stable senescent compartment. Conclusions: The result is an externally benchmarked, novelty-annotated senotherapeutic candidate map, offered as convergent confirmation of repurposable mechanisms rather than a claim of new drug classes.
Aygüneş-Jafari D, Düzgün Z Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study. Biomedicines. 2026. doi:10.3390/biomedicines14102286. PMID: 42940092. https://pubmed.ncbi.nlm.nih.gov/42940092/
Related research
New fluorescent sensor detects cells aging from cancer and lung drugs
Researchers built a glowing probe that lights up only in certain aged cells. It may help scientists track these cells in living animals, but this is early lab work.
Mixing a senescence-clearing drug with trametinib slowed glioma regrowth in mice
Researchers found a drug combination that cleared aging-like tumour cells in mice and slowed regrowth. This does not show the combination would work the same way in children.
A vaccine-style treatment in mice eased diabetes signs and aged cell markers
Mice given a treatment aimed at a virus-like gene showed less weight gain and better blood sugar control. This study was in mice and cells, so it does not show the same would happen in people.
Aging cells that support stem cells may disrupt them through chemical signals
This is a review that pulls together older and newer studies. It proposes a model, but it does not show that the model is true.
Cx43 protein may boost breast cancer drug response in lab tests
Researchers studied a protein called Cx43 that helps cells talk to each other. They found it may help a breast cancer drug slow tumor growth. This early work is not yet checked by other scientists, so it does not show this would help people.
A new vaccine clears aging cells in mice and may extend lifespan
Researchers made a vaccine aimed at old, worn-out cells called senescent cells. In mice, it cleared some of these cells and helped metabolism. This is early work, so it does not show the vaccine would help people.
See all research on Senolytics →